Teva, Regeneron Agree to Mutual Endeavor to Develop Fasinumab

Teva and Regeneron have agreed to develop and commercialize fasinumab. Regeneron will be supplying its investigational antibody, fasinumab, indicated in Phase III clinical development for osteoarthritis pain and in Phase II results of same antibody for chronic low back pain.

Fasinumab is a fully human monoclonal antibody that targets a protein that plays a central role in the monitoring of pain signaling. There is evidence that fasinumab levels are elevated in patients with chronic pain conditions.

It is estimated that 30 million people in the U.S. suffer pain from osteoarthritis and a comparable number with chronic lower back pain, company said.